1.
|
Ministry of Health, Labor and Welfare: The
Dynamic Statistics of the Population in 2005. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei05/hyo7/htmluri.
|
2.
|
Ishii H, Furuse J, Boku N, et al: Phase II
study of gemcitabine chemotherapy alone for locally advanced
pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 40:573–579. 2010.
View Article : Google Scholar : PubMed/NCBI
|
3.
|
Evans DB, Abbruzzese JL and Willett CG:
Cancer of the pancreas. Cancer: Priciples and Practice of Oncology.
De Vita VT Jr, Hellman S and Rosenberg SA: 6th edition. Lippincott,
Williams and Wilkins; Philadelphia: pp. 1126–1161. 2001
|
4.
|
Oettle H, Post S, Neuhaus P, et al:
Adjuvant chemotherapy with gemcitabine vs. observation in patients
undergo curative-intent resection of pancreatic cancer: a
randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar
|
5.
|
Aloia TE, Lee JE, Vauthey JN, et al:
Delayed recovery after pancreaticoduodenectomy: a major factor
impairing the delivery of adjuvant chemotherapy? J Am Coll Surg.
204:347–355. 2007. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Sandy H, Bruckner H, Cooperman A, et al:
Survival advantage of combined chemoradiotherapy compared with
resection as the initial treatment of patients with regional
pancreatic carcinoma. An outcomes trial. Cancer. 89:314–327. 2000.
View Article : Google Scholar
|
7.
|
Ensminger WD, Rosowsky A and Raso V: A
clinical pharmacological evaluation of hepatic arterial infusions
of 5-fluoro-2-deoxyuridine and 5-fluoroufacil. Cancer Res.
38:3789–3792. 1978.PubMed/NCBI
|
8.
|
Vogl TJ, Schwarz W, Eichler K, et al:
Hepatic intraarterial chemotherapy with gemcitabine in patients
with unresectable cholangiocarcinoma and liver metastases of
pancreatic cancer: a clinical study on maximum tolerable dose and
treatment efficacy. J Cancer Res Clin Oncol. 132:745–755. 2006.
View Article : Google Scholar
|
9.
|
Tse AN, Wu N, Patel D, et al: A phase I
study of gemcitabine given via intrahepatic pump for primary or
metastatic hepatic malignancies. Cancer Chemother Pharmacol.
64:935–944. 2009. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Van Riel JM, Peters GJ, Mammatas LH, et
al: A phase I and pharmacokinetic study of gemcitabine given by
24-h hepatic arterial infusion. Euro J Cancer. 45:2519–2527.
2009.PubMed/NCBI
|
11.
|
Nagakawa T, Nagamori M, Futakami F, et al:
Result of extensive surgery for pancreatic carcinoma. Cancer.
77:640–645. 1996. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Noto M, Miwa K, Kitagawa H, et al:
Pancreas head carcinoma. Frequency of invasion to soft tissue
adherent to the superior mesenteric artery. Am J Surg Pathol.
29:1056–1061. 2005.PubMed/NCBI
|
13.
|
Traverso LW: Pancreatic cancer: surgery
alone is not sufficient. Surg Endosc. 20(Suppl 2): 446–449. 2006.
View Article : Google Scholar
|
14.
|
Spitz FR, Abbruzzese JL, Lee JE, et al:
Preoperative and postoperative chemoradiation strategies in
patients treated with pancreaticoduodenectomy for adenocarcinoma of
the pancreas. J Clin Oncol. 15:928–937. 1997.PubMed/NCBI
|
15.
|
Hoffman JP, Lipsitz S, Pisansky T, et al:
Phase II trial of preoperative radiation therapy and chemotherapy
for patients with localized, resectable adenocarcinoma of the
pancreas: an Eastern Cooperative Oncology Group Study. J Clin
Oncol. 16:317–323. 1998.
|
16.
|
Palmer DH, Stocken DD, Hewitt H, et al: A
randomized phase 2 trial of neoadjuvant chemotherapy in resectable
pancreatic cancer: gemicitabine alone versus gemcitabine combined
with cisplatin. Ann Surg Oncol. 14:2088–2096. 2007. View Article : Google Scholar
|
17.
|
Golcher H, Brunner T, Grabenbauer G, et
al: Preoperative chemoradiation in adenocarcinoma of the pancreas.
A single centre experience advocating a new treatment strategy.
EJSO. 34:756–764. 2008. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Turrini O, Viret F, Zabotto LM, et al:
Neoadjuvant 5 fluorouracilcisplatin chemoradiation effect on
survival in patients with resectable pancreatic head
adenocarcinoma: a ten-year single institution experience. Oncology.
76:413–419. 2009.PubMed/NCBI
|
19.
|
Takai S, Satoi S, Yanagimoto H, et al:
Neoadjuvant chemoradiation in patients with potentially resectable
pancreatic cancer. Pancreas. 36:26–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Satoi S, Yanaagimoto H, Toyokawa H, et al:
Surgical results after prepoerative chemoradiation therapy for
patienes with pancreatic cancer. Pancreas. 38:282–288. 2009.
View Article : Google Scholar : PubMed/NCBI
|
21.
|
Cohen AD and Kemeny NE: An update on
hepatic arterial infusion chemotherapy for colorectal cancer.
Oncologist. 8:553–566. 2003. View Article : Google Scholar : PubMed/NCBI
|
22.
|
Mocellin S, Pilati P, Lise M, et al:
Meta-analysis of hepatic arterial infusion for unresectable liver
metastases from colorectal cancer: the end of an era? J Clin Oncol.
25:5649–5654. 2007. View Article : Google Scholar : PubMed/NCBI
|
23.
|
Homma H, Akiyama T, Mezawa S, et al:
Advanced pancreatic carcinoma showing a complete response to
arterial infusion chemotherapy. Int J Clin Oncol. 9:197–201. 2004.
View Article : Google Scholar : PubMed/NCBI
|
24.
|
Miyanishi K, Ishiwatari H and Hayashi T: A
phase I trial lf arterial infusion chemotherapy with gemcitabine
and 5-fluorouracil for unresectable advanced pancreatic cancer
after vascular supply distribution via superselective embolization.
Jpn J Clin Oncol. 38:268–274. 2008. View Article : Google Scholar
|
25.
|
Mogami K, Ichihara T, Sato T, et al: A
case of the papilla lf vater accompanied witn a stricture of the
celiac artery by the median arcuate ligament. Jpn J Gastroenterol
Surg. 41:1588–1593. 2008. View Article : Google Scholar
|
26.
|
Kikuchi K and Kanno H: Comparison for
blood levels and clinical effects between tablet and other dosage
forms of 5-fluorouracil (5-FU). Gan To Kagaku Ryouho. 6:559–565.
1979.
|
27.
|
Maruyama S, Ando M and Watayo T:
Concentration of 5-FU after hepatic artery infusion chemotherapy
for liver metastases of colorectal cancer. Gan To Kagaku Ryouho.
30:1635–1638. 2003.PubMed/NCBI
|